Physician profile
Laura A Doti
NPI 1538381405
$2,955.55
in general payments reported to CMS, 2019-2025
22 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $908 · 2023: $288 · 2024: $460 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.91 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $364.20 | 2021-2025 | |
| Exeltis, USA INC. | $294.32 | 2021-2025 | Slynd |
| Biogen, INC. | $247.63 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $179.49 | 2021-2024 | Twirla |
| Amgen INC. | $172.29 | 2023-2024 | Evenity, Prolia |
| Evofem Biosciences, INC. | $159.38 | 2021-2022 | |
| Coopersurgical, INC. | $151.16 | 2022-2025 | Paragard T 380a |
| Hologic Sales and Service, LLC | $118.77 | 2021-2025 | Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $109.77 | 2021-2022 | |
| Shield Therapeutics INC | $93.55 | 2023-2024 | Accrufer |
| Organon LLC | $76.66 | 2023-2025 | Nexplanon |
| Scynexis, INC. | $74.14 | 2022 | |
| Myovant Sciences INC. | $70.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.44 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $66.55 | 2024 | Veozah |
| Pfizer INC. | $49.80 | 2025 | |
| Avion Pharmaceuticals | $34.99 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $26.56 | 2023 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $25.98 | 2024 | Trintellix |
| Daiichi Sankyo INC. | $22.55 | 2023 | Injectafer |
| Trevena, INC. | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Doti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.